Matches in SemOpenAlex for { <https://semopenalex.org/work/W4294191196> ?p ?o ?g. }
- W4294191196 endingPage "784.e9" @default.
- W4294191196 startingPage "784.e1" @default.
- W4294191196 abstract "Chronic graft-versus-host disease (cGVHD) and its management with immunosuppressive therapies increase the susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, as well as progression to severe Coronavirus 19 disease (COVID-19). Vaccination against COVID-19 is strongly recommended, but efficacy data are limited in this patient population. In this study, responses to COVID-19 vaccination were measured at 3 time points-after the initial vaccine series, before the third dose, and after the third dose-in adults with cGVHD receiving immunosuppressive therapy. Humoral response was measured by quantitative anti-spike antibody and neutralizing antibody levels. Anti-nucleocapsid antibody levels were measured to detect natural infection. T cell response was evaluated by a novel immunosequencing technique combined with immune repertoire profiling from cryopreserved peripheral blood mononuclear cell samples. Present or absent T cell responses were determined by the relative proportion of unique SARS-CoV-2-associated T cell receptor sequences (breadth) plus clonal expansion of the response (depth) compared with those in a reference population. Based on both neutralizing antibody and T cell responses, patients were categorized as vaccine responders (both detected), nonresponders (neither detected), or mixed (one but not both detected). Thirty-two patients were enrolled for the initial series, including 17 (53%) positive responders, 7 (22%) mixed responders, and 8 (25%) nonresponders. All but one patient categorized as mixed responders had humoral responses while lacking T cell responses. No statistical differences were observed in patient characteristics among the 3 groups of patients categorized by immune response, although sample sizes were limited. Significant positive correlations were observed between the robustness of cellular and humoral responses after the initial series. Among the 20 patients with paired samples (pre- and post-third dose), a third vaccination resulted in increased neutralizing antibody titers. cGVHD worsened in 10 patients (26%; 6 after the initial series and 4 after the third dose), necessitating escalation of immunosuppressive doses in 5 patients, although 4 had been tapering immunosuppression and 5 had already worsening cGVHD at the time of vaccination, and a clear association between COVID-19 vaccination and cGVHD could not be drawn. Among the patients with cGVHD on immunosuppressive therapy, 72% demonstrated a neutralizing antibody response after a 2-dose primary COVID-19 vaccination, two-thirds of whom also developed a T cell response; 25% had neither a humoral nor a T cell response. A third dose further amplified the antibody response." @default.
- W4294191196 created "2022-09-02" @default.
- W4294191196 creator A5000958441 @default.
- W4294191196 creator A5005929463 @default.
- W4294191196 creator A5016644532 @default.
- W4294191196 creator A5017952176 @default.
- W4294191196 creator A5019783159 @default.
- W4294191196 creator A5020804933 @default.
- W4294191196 creator A5021949320 @default.
- W4294191196 creator A5031390636 @default.
- W4294191196 creator A5039911143 @default.
- W4294191196 creator A5052240976 @default.
- W4294191196 creator A5069472710 @default.
- W4294191196 date "2022-11-01" @default.
- W4294191196 modified "2023-10-16" @default.
- W4294191196 title "Humoral and Cellular Immune Response to Covid-19 Vaccination in Patients with Chronic Graft-versus-Host Disease on Immunosuppression" @default.
- W4294191196 cites W1989223689 @default.
- W4294191196 cites W2379365975 @default.
- W4294191196 cites W3047483639 @default.
- W4294191196 cites W3111255098 @default.
- W4294191196 cites W3128807007 @default.
- W4294191196 cites W3156866359 @default.
- W4294191196 cites W3165091170 @default.
- W4294191196 cites W3173185194 @default.
- W4294191196 cites W3174317300 @default.
- W4294191196 cites W3175432865 @default.
- W4294191196 cites W3179770364 @default.
- W4294191196 cites W3183171079 @default.
- W4294191196 cites W3183558279 @default.
- W4294191196 cites W3190398149 @default.
- W4294191196 cites W3192156468 @default.
- W4294191196 cites W3196397911 @default.
- W4294191196 cites W3196516725 @default.
- W4294191196 cites W3200680525 @default.
- W4294191196 cites W3202007017 @default.
- W4294191196 cites W3204248407 @default.
- W4294191196 cites W3207290229 @default.
- W4294191196 cites W3216299183 @default.
- W4294191196 cites W3217201218 @default.
- W4294191196 cites W3217284394 @default.
- W4294191196 cites W4200087343 @default.
- W4294191196 cites W4200298142 @default.
- W4294191196 cites W4205483821 @default.
- W4294191196 cites W4205628147 @default.
- W4294191196 cites W4210784896 @default.
- W4294191196 cites W4210792795 @default.
- W4294191196 cites W4212843503 @default.
- W4294191196 cites W4213454641 @default.
- W4294191196 cites W4221063781 @default.
- W4294191196 cites W4223448245 @default.
- W4294191196 cites W4224222981 @default.
- W4294191196 cites W4226081507 @default.
- W4294191196 cites W4226096713 @default.
- W4294191196 cites W4229056490 @default.
- W4294191196 cites W4285011326 @default.
- W4294191196 cites W4288753092 @default.
- W4294191196 doi "https://doi.org/10.1016/j.jtct.2022.08.026" @default.
- W4294191196 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36058550" @default.
- W4294191196 hasPublicationYear "2022" @default.
- W4294191196 type Work @default.
- W4294191196 citedByCount "3" @default.
- W4294191196 countsByYear W42941911962023 @default.
- W4294191196 crossrefType "journal-article" @default.
- W4294191196 hasAuthorship W4294191196A5000958441 @default.
- W4294191196 hasAuthorship W4294191196A5005929463 @default.
- W4294191196 hasAuthorship W4294191196A5016644532 @default.
- W4294191196 hasAuthorship W4294191196A5017952176 @default.
- W4294191196 hasAuthorship W4294191196A5019783159 @default.
- W4294191196 hasAuthorship W4294191196A5020804933 @default.
- W4294191196 hasAuthorship W4294191196A5021949320 @default.
- W4294191196 hasAuthorship W4294191196A5031390636 @default.
- W4294191196 hasAuthorship W4294191196A5039911143 @default.
- W4294191196 hasAuthorship W4294191196A5052240976 @default.
- W4294191196 hasAuthorship W4294191196A5069472710 @default.
- W4294191196 hasBestOaLocation W42941911962 @default.
- W4294191196 hasConcept C137061746 @default.
- W4294191196 hasConcept C159654299 @default.
- W4294191196 hasConcept C202751555 @default.
- W4294191196 hasConcept C203014093 @default.
- W4294191196 hasConcept C22070199 @default.
- W4294191196 hasConcept C2776548049 @default.
- W4294191196 hasConcept C2780252810 @default.
- W4294191196 hasConcept C2908647359 @default.
- W4294191196 hasConcept C55493867 @default.
- W4294191196 hasConcept C71924100 @default.
- W4294191196 hasConcept C86803240 @default.
- W4294191196 hasConcept C8891405 @default.
- W4294191196 hasConcept C99454951 @default.
- W4294191196 hasConceptScore W4294191196C137061746 @default.
- W4294191196 hasConceptScore W4294191196C159654299 @default.
- W4294191196 hasConceptScore W4294191196C202751555 @default.
- W4294191196 hasConceptScore W4294191196C203014093 @default.
- W4294191196 hasConceptScore W4294191196C22070199 @default.
- W4294191196 hasConceptScore W4294191196C2776548049 @default.
- W4294191196 hasConceptScore W4294191196C2780252810 @default.
- W4294191196 hasConceptScore W4294191196C2908647359 @default.
- W4294191196 hasConceptScore W4294191196C55493867 @default.
- W4294191196 hasConceptScore W4294191196C71924100 @default.